Role of Zonisamide in Advanced Parkinson’s Disease (PD) in Egyptian Population: Pilot Study

Overview

Zonisamide (ZNS) (1,2-Benzisoxazole-3-methanesulfonamide) is an anti-epileptic drug. In three double blinded placebo controlled studies, ZNS- as an adjunctive treatment- showed beneficial effects on motor symptoms of PD with a low incidence of adverse events. As a result 25 mg daily of ZNS was approved in 2009 in Japan as an adjunctive treatment in PD patients whose condition responded insufficiently to Levodopa treatment.

Most observations of a beneficial effect of ZNS have been in Japanese people, and the antiparkinsonian mechanism of action is unclear. So, ZNS is a promising but still investigational drug to treat PD and more studies are warranted.

this study will investigate the efficacy and tolerability of Zonisamide as an adjunctive treatment in Egyptian patients with advanced PD, including motor fluctuations, levodopa induced dyskinesia and existing nonmotor symptoms. Additionally it investigates its effects on quality of life of PD patients.

Full Title of Study: “Role of Zonisamide in Advanced Parkinson’s Disease (PD) in Egyptian Population: Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 1, 2021

Detailed Description

Type of Study: Randomized double blinded Placebo controlled study.

- Study Setting: Movement disorders clinic of neurology department, Ain Shams University Hospitals.

- Study Period : 2 years.

- Study Population: Patients with advanced PD and insufficient response to dopaminergic drugs .

Inclusion Criteria:

- Age older than 18 years of both male and female genders.

- Individuals diagnosed with PD based on the presence of 2 of 3 cardinal features & United Kingdom bank criteria for idiopathic Parkinson's disease.

- Patients with manifestations of advanced PD defined according to the consensus on the definition of advanced PD.

- Inadequate response to dopaminergic medications due to limitations related to side effects, or levodopa related long-term problems as wearing-off phenomena, "on"-"off" fluctuation, levodopa induced dyskinesia and freezing phenomena, no-"on" and delayed-"on,".

Exclusion Criteria:

1. Patients with atypical or secondary parkinsonian syndromes excluding PD.

2. Patients who could not perform the tests.

3. Women who were or might be pregnant, who did not practice effective contraception and were of childbearing potential, or who were breastfeeding.

Ethical Considerations:

All of the patients will be informed of the objectives, procedures and possible benefits and risks of the study and will provide written voluntary consent.

The study will conform to the standards of the Ethical Review Committee, Ain Shams University.

Study Procedures:

- Patients diagnosed with PD will be evaluated for inclusion and exclusion criteria. Eligible patients will be randomly assigned to one of three groups: placebo group , ZNS group 25 mg and ZNS group 50 mg (30 patients each).In ZNS 50 mg group, ZNS will be started with a dose of 25 mg daily for one week then increased to 50 mg once daily to minimize side effects. The dosage and regimen of ongoing antiparkinsonian drugs and other drugs that may affect PD symptoms will remain unchanged one month before and through the treatment period.

Interventions

  • Drug: Zonisamide Capsules
    • anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients

Arms, Groups and Cohorts

  • Active Comparator: Patients 25 ZNS
    • 30 patients receive oral 25 mg ZNS daily
  • Active Comparator: Patients 50 ZNS
    • 30 patients receive oral 50 mg ZNS daily
  • Placebo Comparator: Patients Placebo
    • 30 patients receive placebo

Clinical Trial Outcome Measures

Primary Measures

  • Off motor daily time
    • Time Frame: at 1 and 3 months
    • assessing change of Off and on time using Movement Disorders Society- Unified Parkinson’s Disease Rating Scale (MDS UPDRS)
  • levodopa related Dyskinesia
    • Time Frame: at 1 and 3 months
    • Dyskinesia will also be evaluated with Movement Disorders Society- Unified Dyskinesia Rating Scale (MDS-UDysRS)

Secondary Measures

  • Quality of life (daily life activities)
    • Time Frame: at 3 months
    • parkinson disease questionnaire-39
  • cognitive outcome
    • Time Frame: at 3 months
    • using Montreal cognitive assessment
  • The non-motor symptoms scales
    • Time Frame: at 1 and 3 months
    • using The non-motor symptoms scales (NMSS)

Participating in This Clinical Trial

Inclusion Criteria

1 -Age older than 18 years of both male and female genders. 2-Individuals diagnosed with PD based on the presence of 2 of 3 cardinal features & UK bank criteria for idiopathic Parkinson's disease. 3-Patients with motor complications of PD (Hoehn and Yahr stage 2-3)(on therapy) and at least 2 hours off time.

Exclusion Criteria

1 -Patients with atypical or secondary Parkinsonism syndromes excluding PD. 2-Patients who could not perform the tests. 3-Women who were or might be pregnant, who did not practice effective contraception and were of childbearing potential, or who were breastfeeding.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ain Shams University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ali Shalash, professor of Neurology – Ain Shams University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.